Kane Biotech Inc.
KNBIF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,081 | $149 | $2,668 | $1,608 |
| % Growth | 1,296.8% | -94.4% | 66% | – |
| Cost of Goods Sold | $1,209 | $40 | $1,255 | $1,039 |
| Gross Profit | $872 | $109 | $1,413 | $568 |
| % Margin | 41.9% | 73.5% | 53% | 35.4% |
| R&D Expenses | $1,717 | $1,287 | $1,054 | $1,377 |
| G&A Expenses | $3,078 | $2,413 | $3,723 | $4,075 |
| SG&A Expenses | $3,078 | $2,413 | $3,723 | $4,075 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$233 | $0 | $0 |
| Operating Expenses | $4,795 | $3,467 | $4,777 | $5,452 |
| Operating Income | -$3,923 | -$3,357 | -$3,458 | -$4,884 |
| % Margin | -188.5% | -2,253.6% | -129.6% | -303.7% |
| Other Income/Exp. Net | -$548 | -$1,205 | -$564 | $34 |
| Pre-Tax Income | -$4,471 | -$4,562 | -$4,022 | -$4,850 |
| Tax Expense | -$1,310 | $0 | $0 | $0 |
| Net Income | $6,098 | -$5,034 | -$3,890 | -$4,605 |
| % Margin | 293% | -3,379% | -145.8% | -286.4% |
| EPS | -0.024 | -0.033 | -0.033 | -0.041 |
| % Growth | 27.4% | 2.4% | 18.6% | – |
| EPS Diluted | -0.024 | -0.036 | -0.033 | -0.041 |
| Weighted Avg Shares Out | 133,906 | 140,265 | 120,702 | 112,600 |
| Weighted Avg Shares Out Dil | 133,906 | 127,120 | 120,702 | 112,600 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $6 | $15 | $122 |
| Interest Expense | $545 | $1,215 | $817 | $416 |
| Depreciation & Amortization | $218 | $116 | $258 | $188 |
| EBITDA | -$3,707 | -$3,234 | -$2,947 | -$4,246 |
| % Margin | -178.2% | -2,171% | -110.5% | -264.1% |